Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Pharmacol Biochem Behav. 2008 Oct;90(4):569–577. doi: 10.1016/j.pbb.2008.04.017

Figure 2. Effects of PCP administration (PN7 only) the development of locomotor sensitization.

Figure 2

Locomotor sensitization induced by a 4 mg/kg challenge to PCP treatment on PN7 treated animals as measured on PN28–35. Pretreatment on PN7 with olanzapine (1 mg/kg) or risperidone (0.25 mg/kg) inhibits the development of locomotor sensitization N=8/group (top). Time-course of locomotor activity (bottom) *p<0.05 vs. saline (one-way ANOVA with Bonferroni’s post hoc test). N=8 in both control and experimental groups. ●-saline; ○-10 mg/kg PCP; ▼-1 mg/kg olanzapine; Δ-olanzapine + PCP; ■-0.25 mg/kg risperidone; □-risperidone + PCP

HHS Vulnerability Disclosure